By Faith Ashmore, Benzinga
The integration of Artificial Intelligence (AI) in biotechnology is rapidly gaining momentum, revolutionizing the field of life sciences. AI technologies, such as machine learning and deep learning algorithms, have the potential to analyze complex biological data more efficiently and accurately than ever before. AI algorithms can analyze vast amounts of genomic, proteomic, and clinical data, leading to new insights and discoveries that were previously inaccessible. This integration of AI and biotech holds great promise for enhancing scientific understanding, improving healthcare outcomes, and ultimately transforming the way we approach biotechnological advancements.
Mainz Biomed (NASDAQ: MYNZ) , a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, has created ColoAlert®, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. This non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. The company has recently formed a partnership with Liquid Biosciences, aiming to leverage the capabilities of AI in developing an advanced colorectal screening test.
Its partnership with Liquid Biosciences will help expand the company’s existing cutting-edge products. Recently, Mainz Biomed conducted a multi-center international clinical trial in Germany and Norway to evaluate the effectiveness of incorporating mRNA biomarkers into ColoAlert®, their leading product for colorectal cancer (CRC) screening. The study yielded impressive findings, demonstrating a high sensitivity of 94.4% and specificity of 97.5% for detecting CRC. Additionally, the screening test showed a sensitivity of 80% and specificity of 95.2% in detecting precursor lesions, including advanced adenomas that may develop into CRC. These results were nothing short of groundbreaking for the company.
The partnership with Liquid Biosciences has the potential to move the needle forward more as Liquid Biosciences has a history of using AI to advance similar technologies. Liquid Biosciences has made a significant impact on the life sciences industry with its EMERGE bio-analytics platform. This platform has been utilized in more than 240 projects for prominent pharmaceutical companies and emerging therapeutic and diagnostic firms. It plays a crucial role in various areas such as biomarker discovery, clinical trial screening, and post-FDA approval services including patient treatment selection and optimal dosing regimens.
“As artificial intelligence continues to disrupt every aspect of the healthcare sector, we are excited to establish a robust partnership with a genuine leader in the field as we head into the final development stage of our next-generation CRC screening test,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “We look forward to continuing our highly productive partnership with the Liquid Biosciences team as we execute on our mission to bring the most effective self-administered cancer detection products to the market.”
Liquid Biosciences reports that what makes EMERGE truly stand out from other AI and machine learning solutions is its exceptional computational speed and ability to handle a vast amount of variables. It operates without making any assumptions or constraints, allowing for an unbiased and scalable approach. The platform's transparency and ability to generate algorithms from complex data without prior assumptions enable the identification of variables that may have low expression but hold functional significance due to the intricate interactions inherent in complex biological systems.
“We are excited to extend our relationship with Mainz Biomed into a formal partnership as we take great pride in working with companies who represent disruptive innovation that will impact disease prevention and treatment,” shared Patrick Lilley, Chief Executive Officer of Liquid Biosciences. “The work Mainz Biomed is doing will be crucial to saving lives from a disease where mortality is driven by late detection. As such, we are very pleased to have the opportunity to play an integral role in helping it develop the next generation of its pioneering products.”
This partnership with Liquid Biosciences comes after a string of previous partnerships with other industry leaders like Zöller-Kipper and Ärztliches Labor Dr. Buhlmann. Through the partnership between Mainz Biomed and German company, Zöller-Kipper, accessibility to ColoAlert® test has been greatly enhanced for both patients and healthcare providers. All of Zöller-Kipper’s over 2,500 employees can now easily request the test through Mainz Biomed's online portal and have it delivered to their doorstep. Once the sample is received and processed, the employee can access their confidential test results through the portal. The portal also provides an explanation of the results to ensure that the employee understands them and if the employee has given consent for their physician to be notified, the doctor can directly follow up with them based on the test results.
With colorectal cancer being the third most prevalent form of cancer and a troubling trend of this cancer affecting more and more young people, the need for biotech companies to innovate detection and treatment could not be understated. Mainz Biomed’s commitment to pushing the boundaries of diagnostic technology, increasing accessibility, and its growth trajectory seems to be making it a force to be reckoned with in the industry, setting it apart from its competitors.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.